Sumitomo Pharma Co., Ltd. (TYO:4506)
1,501.00
-28.00 (-1.83%)
Jun 30, 2026, 3:30 PM JST
Sumitomo Pharma Employees
Sumitomo Pharma had 3,832 employees as of March 31, 2025. The number of employees decreased by 1,148 or -23.05% compared to the previous year.
Employees
3,832
Change (1Y)
-1,148
Growth (1Y)
-23.05%
Revenue / Employee
118.29M JPY
Profits / Employee
27.89M JPY
Market Cap
685.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 3,832 | -1,148 | -23.05% |
| Mar 31, 2024 | 4,980 | -1,270 | -20.32% |
| Mar 31, 2023 | 6,250 | -737 | -10.55% |
| Mar 31, 2022 | 6,987 | 165 | 2.42% |
| Mar 31, 2021 | 6,822 | 365 | 5.65% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Eisai | 10,543 |
| Toho Holdings | 7,609 |
| Shionogi & | 6,223 |
| Towa Pharmaceutical | 4,788 |
| Tsumura & Co. | 4,272 |
| Sawai Group Holdings | 3,310 |
| Nippon Shinyaku | 2,243 |
| Kissei Pharmaceutical | 1,778 |
Sumitomo Pharma News
- 14 days ago - Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia - Business Wire
- 19 days ago - Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia - Business Wire
- 4 weeks ago - Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 - Business Wire
- 6 weeks ago - New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH - Business Wire
- 6 weeks ago - Sumitomo Pharma Earnings Call Transcript: Q4 2026 - Transcripts
- 6 weeks ago - Sumitomo Pharma Quarterly report: Q4 2026 - Filings
- 6 weeks ago - Sumitomo Pharma Slides: Q4 2026 - Filings
- 4 months ago - Sumitomo Pharma Slides: Investor presentation - Filings